XETRA - Delayed Quote EUR

Bayer Aktiengesellschaft (BAYN.DE)

26.97

-0.38

(-1.37%)

At close: 5:35 PM GMT+2

Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales

Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.

Zacks 9 hours ago

ROG.SW

BAYRY
Pharmaceutical giant Bayer’s manager cull will likely affect thousands of bosses—and the aspirin inventor thinks it will help its ‘brilliant’ Gen Z grads to thrive

Bayer currently has more than twelve tiers between management and its customers in some departments, and the aim of CEO Bill Anderson is to reduce that to around five or six.

Fortune 11 hours ago

BAYRY
How Roundup lawsuits could give China an edge

Legal fees associated with Bayer's Roundup, a weed-killing product used by farmers and gardeners who want to protect their crops or yards, have cost the company significantly.

Fox Business 11 days ago

BAYN.DE
-1.37%
Pharmaceutical giant Bayer is getting rid of bosses and asking nearly 100,000 workers to ‘self-organize’ to save $2.15 billion

Chief executive Bill Anderson says he doesn’t want it to be a "lame" company, but its stock has still tanked 50%.

Fortune 13 days ago

BAYN.DE
-1.37%
Google Partners With European Conglomerate Bayer For New AI-Powered Solutions For Radiologists

On Tuesday, Bayer AG (OTC:BAYRY) and Alphabet Inc’s (NASDAQ:GOOG) (NASDAQ:GOOGL) Google Cloud announced a collaboration to develop artificial intelligence (AI) solutions to support radiologists. As part of the collaboration, Bayer will further develop its platform to accelerate the development and deployment of AI-powered healthcare applications with a clear focus on radiology, using Google Cloud’s technology, including its generative AI (gen AI) tools. The collaboration aims to help organizatio

Benzinga 15 days ago

GOOG

BAYN.DE
-1.37%
Here’s Why Bayer Aktiengesellschaft (BAYRY) Detracted in Q1

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. For the quarter ended March 31, 2024, the fund returned 0.11% compared to the MSCI World ex U.S. Index benchmark’s 5.59% return. Since its inception in September 1992, the fund returned an […]

Insider Monkey 16 days ago

BAYN.DE
-1.37%
Judge slashes Bayer $1.56 billion Roundup verdict to $611 million

A Missouri judge slashed a $1.56 billion verdict against Bayer to $611 million for three people who claimed its Roundup weed killer caused their cancer, by reducing punitive damages. Bayer said on Friday it is appealing. The German company's Monsanto unit had been found liable in November by a Cole County, Missouri, jury to Valorie Gunther of New York, Jimmy Draeger of Missouri and Daniel Anderson of California, who blamed their non-Hodgkin's lymphoma on their exposure to Roundup.

Reuters 19 days ago

BAYRY
Bayer’s $1.5 Billion Roundup Verdict Slashed to $600 Million

(Bloomberg) -- Bayer AG’s Monsanto unit persuaded a Missouri judge to cut almost $1 billion from a $1.5 billion jury verdict that was one of the largest in the six years the company has been fighting thousands of claims that its Roundup weedkiller causes cancer.Most Read from BloombergRBC Fires CFO Ahn After Probe Into Personal RelationshipTrumpism Is Emptying ChurchesSaudis Scale Back Ambition for $1.5 Trillion Desert Project NeomTurkey Joins NATO Allies in Suspending Europe Arms TreatyThe Odds

Bloomberg 19 days ago

BAYRY
Bayer-Backed Boundless Bio Falls 11% After $100 Million IPO

(Bloomberg) -- Shares of Boundless Bio Inc., a cancer therapeutics maker that counts Bayer AG among its largest investors, fell nearly 11% after raising $100 million in a US initial public offering.Most Read from BloombergChina Factory Activity Expands for First Time in Six MonthsAT&T Says Data From 73 Million Accounts Leaked on Dark WebUS Oil Suppliers Muscling Into OPEC+ Markets All Over the WorldBank of Russia Sees No Alternative to Yuan for Its ReservesInvestors Spoiled for Choice With Top I

Bloomberg 27 days ago

BAYN.DE
-1.37%
Bayer-Backed Drug Maker Boundless Bio Raises $100 Million in IPO

(Bloomberg) -- Boundless Bio Inc., a cancer therapeutics maker that counts Bayer AG among its largest investors, raised $100 million in a US initial public offering after pricing shares at the midpoint of a marketed range.Most Read from BloombergLondon Insurers Face Baltimore Bridge Payouts Worth BillionsBiden Gains Ground Against Trump in Six Key States, Poll ShowsJapan Amps Up Intervention Threat as Yen Hits Lowest Since 1990Trump’s Net Worth Hits $6.5 Billion, Making Him One of World’s 500 Ri

Bloomberg 27 days ago

BAYN.DE
-1.37%
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges

Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.

Zacks 30 days ago

BAYN.DE
-1.37%
PFE
Thermo Fisher (TMO) Inks Deal to Develop Companion Diagnostics

Thermo Fisher's (TMO) new partnership with Bayer AG is likely to help increase the latter's precision cancer therapies.

Zacks last month

TMO

BAYRY

CAH
One CEO’s Radical Fix for Corporate Troubles: Purge the Bosses

Bayer Chief Executive Bill Anderson is throwing out the corporate playbook for a management plan that shifts more decisions to workers.

The Wall Street Journal last month

BAYRY

BAYZF
New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding

Several blood thinners are being developed that could prevent the clots that cause heart attacks and strokes—without some of the side effects.

The Wall Street Journal last month

BMY

CELG-RT

MRK
Bayer CEO: Corporate bureaucracy belongs in the 19th century. Here’s how we’re fighting it

Adverse jury decisions and a pipeline setback have sent Bayer's share price to a nearly 20-year low.

Fortune last month

BAYRY
Bayer streamlines pharma leadership team amid company shakeup

The executive team will reportedly shrink from 14 to eight in the latest step in new CEO Bill Anderson’s plan to slash management and reduce “bureaucracy” at the healthcare conglomerate.

BioPharma Dive last month

BAYRY
Bayer's (BAYRY) Elinzanetant Meets Goals in Third Phase III Study

Bayer's (BAYRY) pipeline candidate, elinzanetant, achieves primary and secondary goals in late-stage OASIS 3 study supporting submissions for marketing authorization.

Zacks last month

BAYRY
With new data, Bayer readies rival to Astellas menopause drug

Following a third successful Phase 3 trial, the company is planning approval filings for the medicine, which it acquired in a $425 million deal four years ago.

BioPharma Dive last month

ALPMY

BAYRY
Bayer CEO: Now is not the time to break the company up

Life sciences company Bayer (BAYRY, BAYN.DE) isn't breaking itself up right now. Bayer CEO Bill Anderson says, "This is not a good time to be... breaking up the firm," given the company's need to rebuild its pharmaceutical pipeline and battle the ongoing litigation stemming from the weedkiller Roundup. When it comes to the Roundup lawsuits, Bayer has "adequately provisioned" for the costs of those suits, Anderson says. Overall, "the fundamental fact is, that glyphosate, Roundup, is safe," Anderson states, adding that Bayer is "a scientifically-driven company and we have this litigation thing that's not scientific." On the pharmaceutical business, Anderson says the group is "in a bit of a transition phase." "We got a couple of major medicines that are losing patent protection over the next few years. So we are busy rebuilding the pipeline right now," he tells Yahoo Finance. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich.

Yahoo Finance Video last month

BAYRY

BAYZF
Inflation: Over-the-counter drug prices leap year over year

Alongside other sectors of the consumer economy, nonprescription drug prices saw prices rise 9.3% year-over-year. The insurance industry, health insurance and auto insurance providers in particular, have been beset by inflationary challenges. Yahoo Finance Health Reporter Anjalee Khemlani details the price trends for over-the-counter drugs, referencing a statement from Bayer (BAYRY) from its third-quarter 2023 in relation to how pharmaceutical companies are trying to offset inflation. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.

Yahoo Finance Video last month

BAYRY

BAYZF

Performance Overview

Return	BAYN.DE	DAX PERFORMANCE-INDEX
YTD	-19.80%	+7.98%
1-Year	-53.70%	+13.90%
3-Year	-44.74%	+18.38%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bayer Aktiengesellschaft (BAYN.DE)

Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales

Pharmaceutical giant Bayer’s manager cull will likely affect thousands of bosses—and the aspirin inventor thinks it will help its ‘brilliant’ Gen Z grads to thrive

How Roundup lawsuits could give China an edge

Pharmaceutical giant Bayer is getting rid of bosses and asking nearly 100,000 workers to ‘self-organize’ to save $2.15 billion

Google Partners With European Conglomerate Bayer For New AI-Powered Solutions For Radiologists

Here’s Why Bayer Aktiengesellschaft (BAYRY) Detracted in Q1

Judge slashes Bayer $1.56 billion Roundup verdict to $611 million

Bayer’s $1.5 Billion Roundup Verdict Slashed to $600 Million

Bayer-Backed Boundless Bio Falls 11% After $100 Million IPO

Bayer-Backed Drug Maker Boundless Bio Raises $100 Million in IPO

Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges

Thermo Fisher (TMO) Inks Deal to Develop Companion Diagnostics

One CEO’s Radical Fix for Corporate Troubles: Purge the Bosses

New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding

Bayer CEO: Corporate bureaucracy belongs in the 19th century. Here’s how we’re fighting it

Bayer streamlines pharma leadership team amid company shakeup

Bayer's (BAYRY) Elinzanetant Meets Goals in Third Phase III Study

With new data, Bayer readies rival to Astellas menopause drug

Bayer CEO: Now is not the time to break the company up

Inflation: Over-the-counter drug prices leap year over year

Performance Overview